Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:757-758 (14 April), doi:10.1136/bmj.39168.568692.BE
Theoretical promise of benefit does not translate to improvements in morbidity and mortality
| The first 150 words of the full text of this article appear below. |
In this week's BMJ, Adhikari and colleagues report a systematic review of the impact of inhaled nitric oxide on physiological outcomes, morbidity, and mortality in people with acute respiratory distress syndrome.1 They found that nitric oxide resulted in a limited improvement in oxygenation but did not reduce mortality (risk ratio 1.10; 95% confidence interval 0.94 to 1.30), the duration of ventilation, or the number of days free of ventilation.
Acute respiratory distress syndrome is an important public health problem. It is a catastrophic form of acute respiratory failure that arises after pulmonary (for example, pneumonia or aspiration of gastric contents) or extrapulmonary (for example, sepsis or polytrauma) insults. Not only does it have an incidence as high as 64 cases per 100 000 people per year,2 but it has a high mortality rate (30-60% in unselected populations) and risk of subsequent morbidity in survivors.3
The many cellular and molecular
Niall D Ferguson, assistant professor
Toronto Western Hospital, Toronto, ON, Canada M5T 2S8
n.ferguson@utoronto.ca
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+